Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.

Robert Wessman, executive chairman of the rapidly growing generics company Alvogen, talks about the future of the generics industry, how to build a global generics company, and founding the Icelandic biosimilars manufacturer, Alvotech.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2016.